At 11.0% CAGR, Asia Pacific Prefilled Syringe Market is Projected to be Worth US$ 2,820.57 Million by 2030, Says Business Market Insights

According to Business Market Insights' research, the Asia Pacific prefilled syringe market was valued at US$ 1,225.22 million in 2022 and is expected to reach US$ 2,820.57 million by 2030, registering a CAGR of 11.0% from 2022 to 2030. Strategic initiatives by market players and growing adoption of self-injecting parenteral devices are among the critical factors attributed to the Asia Pacific prefilled syringe market expansion.

Self-injecting parenteral devices are gaining popularity due to the ease of use and ability to improve patient outcomes. These devices are designed to allow patients to self-administer medications at home or on the go and do not require assistance from healthcare professionals. These self-injection devices can help patients manage their symptoms more effectively and improve their quality of life. Moreover, self-injecting devices offer several advantages over traditional injection methods, such as the reduced risk of needlestick injuries, improved medication adherence, and reduction in overall healthcare costs. They also provide patients with greater control over their treatment, enabling them to adjust dosages and timing according to their individual needs.

Further, pharmaceutical companies are increasingly investing in the development of self-injecting parenteral devices for prefilled syringes, and healthcare providers are encouraging their use as a part of a broader shift toward patient-centered care. With the ongoing advancements in technology and design, self-injecting devices will likely continue to gain popularity in the coming years.

On the contrary, increasing product recalls hampers the growth of Asia Pacific prefilled syringe market.

Based on type, the Asia Pacific prefilled syringe market is bifurcated into disposable prefilled syringes and reusable prefilled syringes. The disposable prefilled syringes segment held 72.7% share of the Asia Pacific prefilled syringe market in 2022, amassing US$ 890.22 million. It is projected to garner US$ 2,094.35 million by 2030 to expand at 11.3% CAGR during 2022-2030.

Based on material, the Asia Pacific prefilled syringe market is bifurcated into glass prefilled syringes and plastic prefilled syringes. The glass prefilled syringes segment held 58.6% share of the Asia Pacific prefilled syringe market in 2022, amassing US$ 718.38 million. It is projected to garner US$ 1,623.23 million by 2030 to expand at 10.7% CAGR during 2022-2030.

Based on designs, the Asia Pacific prefilled syringe market is bifurcated into single chamber and multi chamber. The single chamber segment held 67.3% share of the Asia Pacific prefilled syringe market in 2022, amassing US$ 825.18 million. It is projected to garner US$ 1,758.71 million by 2030 to expand at 9.9% CAGR during 2022-2030.

In terms of application, the Asia Pacific prefilled syringe market is segmented into cancer, diabetes, autoimmune disease, infectious diseases, and others. The others segment held 30.2% share of the Asia Pacific prefilled syringe market in 2022, amassing US$ 369.85 million. It is projected to garner US$ 816.04 million by 2030 to expand at 10.4% CAGR during 2022-2030.

By distribution channel, the Asia Pacific prefilled syringe market is segmented into hospital pharmacy, retail pharmacy, and online channel. The hospital pharmacy segment held 55.8% share of Asia Pacific prefilled syringe market in 2022, amassing US$ 683.49 million. It is projected to garner US$ 1,628.13 million by 2030 to expand at 11.5% CAGR during 2022-2030.

Based on country, the Asia Pacific prefilled syringe market is categorized into China, Japan, Australia, India, South Korea, and the Rest of Asia Pacific. China held 25.4% share of Asia Pacific prefilled syringe market in 2022, amassing US$ 310.62 million. It is projected to garner US$ 756.24 million by 2030 to expand at 11.8% CAGR during 2022-2030.

Key players operating in the Asia Pacific prefilled syringe market are B Braun SE, Shandong Weigao Group Medical Polymer Co Ltd, Gerresheimer AG, Schott AG, Nipro Corp, Becton Dickinson and Co, Baxter International Inc, Terumo Corp, and Ypsomed Holding AG, among others.

• In Jan 2020, Gerresheimer expanded its range of pre-fillable polymer syringes. The company launched the Gx RTF ClearJect polymer needle syringe, 2.25 ml.
  
  
• In May 2023, BD increased customer access to an all-in-one prefilled flush syringe with an integrated disinfection unit meant to reinforce infection prevention principles and streamline nurse workflow. The BD PosiFlush SafeScrub is a prefilled saline flush syringe with an active disinfection unit incorporated straight into the tip cap that has been shown in vitro to drastically minimise bacteria growth associated with CRBSIs.
  
  
  
  Contact Us
  Phone: +16467917070
  Email Id: sales@businessmarketinsights.com